rs72554665

Variant summary

Our verdict is Likely pathogenic. Variant got 7 ACMG points: 8P and 1B. PP5_Very_StrongBP4

The NM_001360016.2(G6PD):​c.1376G>T​(p.Arg459Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000133 in 1,209,798 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 44 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: 𝑓 0.00025 ( 0 hom., 12 hem., cov: 23)
Exomes 𝑓: 0.00012 ( 0 hom. 32 hem. )

Consequence

G6PD
NM_001360016.2 missense

Scores

6
5
5

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:15O:4

Conservation

PhyloP100: 3.69
Variant links:
Genes affected
G6PD (HGNC:4057): (glucose-6-phosphate dehydrogenase) This gene encodes glucose-6-phosphate dehydrogenase. This protein is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. G6PD is remarkable for its genetic diversity. Many variants of G6PD, mostly produced from missense mutations, have been described with wide ranging levels of enzyme activity and associated clinical symptoms. G6PD deficiency may cause neonatal jaundice, acute hemolysis, or severe chronic non-spherocytic hemolytic anemia. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 7 ACMG points.

PP5
Variant X-154532269-C-A is Pathogenic according to our data. Variant chrX-154532269-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 100058.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-154532269-C-A is described in Lovd as [Pathogenic]. Variant chrX-154532269-C-A is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.014364898). . Strength limited to SUPPORTING due to the PP5.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
G6PDNM_001360016.2 linkuse as main transcriptc.1376G>T p.Arg459Leu missense_variant 12/13 ENST00000393562.10 NP_001346945.1
G6PDNM_000402.4 linkuse as main transcriptc.1466G>T p.Arg489Leu missense_variant 12/13 NP_000393.4
G6PDNM_001042351.3 linkuse as main transcriptc.1376G>T p.Arg459Leu missense_variant 12/13 NP_001035810.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
G6PDENST00000393562.10 linkuse as main transcriptc.1376G>T p.Arg459Leu missense_variant 12/131 NM_001360016.2 ENSP00000377192 P4P11413-1

Frequencies

GnomAD3 genomes
AF:
0.000250
AC:
28
AN:
112037
Hom.:
0
Cov.:
23
AF XY:
0.000351
AC XY:
12
AN XY:
34197
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00781
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000813
AC:
148
AN:
181938
Hom.:
0
AF XY:
0.000584
AC XY:
39
AN XY:
66812
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000366
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0107
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000121
AC:
133
AN:
1097708
Hom.:
0
Cov.:
37
AF XY:
0.0000881
AC XY:
32
AN XY:
363134
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000284
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00407
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.000195
GnomAD4 genome
AF:
0.000250
AC:
28
AN:
112090
Hom.:
0
Cov.:
23
AF XY:
0.000350
AC XY:
12
AN XY:
34260
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00784
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.000276
ExAC
AF:
0.000577
AC:
70

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:15Other:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:6
Pathogenic, criteria provided, single submitterclinical testingMendelicsMay 04, 2022- -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityDec 21, 2023- -
Pathogenic, criteria provided, single submittercurationDunham Lab, University of WashingtonAug 12, 2022Variant found in unrelated hemizygotes with deficiency, some with anemia, jaundice, and kernicterus (PS4_M, PP4). Segregates with deficiency in multiple unrelated families (PP1). Decreased activity in red blood cells (1-52%) (PS3). Affects same amino acid as pathogenic 459R>P (ClinVar ID 10422) (PM5). Predicted to be disease causing by Mutation Taster and possibly damaging by PolyPhen (PP3). Below expected carrier frequency in gnomAD (PM2). Reported as pathogenic by multiple clinical testing groups (PP5). Post_P 0.9997 (odds of pathogenicity 28416, Prior_P 0.1). -
Pathogenic, criteria provided, single submitterclinical testingVictorian Clinical Genetics Services, Murdoch Childrens Research InstituteDec 21, 2023Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with G6PD deficient haemolytic anaemia (favism) (MIM#300908). (I) 0109 - This gene is associated with X-linked recessive disease. Hemizygous males and homozygous females are commonly affected; however, some heterozygous female carriers can also be affected depending on X-inactivation. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to leucine. (I) 0253 - This variant is hemizygous. (I) 0305 - Variant is present in gnomAD >=0.01 and <0.03 for a recessive condition in the East Asian subpopulation (115 heterozygotes, 0 homozygotes, 43 hemizygotes). (I) 0309 - Multiple alternative amino acid changes at the same position have been observed in gnomAD (v2) (highest allele count: 1 heterozygote, 0 homozygotes, 1 hemizygote). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated glucose-6-phosphate dehydrogenase, C-terminal domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported many times as pathogenic, is referred to as the Canton variant, and is enriched in East Asian populations (ClinVar, PMID: 36315991). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
Pathogenic, criteria provided, single submitterclinical testingCounsylJun 06, 2015- -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 29, 2024This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 459 of the G6PD protein (p.Arg459Leu). This variant is present in population databases (rs72554665, gnomAD 1.0%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with glucose-6-phosphate deficiency (PMID: 1562739, 2263506, 6714986, 8537082, 10643148, 11499668, 17726510, 20203002, 21446359, 25541721, 25775246, 26823837). It has also been observed to segregate with disease in related individuals. This variant is also known as Canton variant. ClinVar contains an entry for this variant (Variation ID: 100058). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on G6PD protein function. Experimental studies have shown that this missense change affects G6PD function (PMID: 16607506). For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:4
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 02, 2021The G6PD c.1376G>T; p.Arg459Leu variant (rs72554665) is reported in the literature in the hemizygous, homozygous, and compound heterozygous states in individuals of East Asian descent affected with G6PD deficiency (Fu 2018, Stevens 1990, Tang 1992). Individuals carrying this variant have been shown to have G6PD enzymatic activity lower than levels found in the general Chinese population (Tang 1992) and this variant has been reported in 27.5% of positive newborn screens for G6PD deficiency in Guangxi, China (Fu 2018). The variant is reported in ClinVar (Variation ID: 100058), and it is found in the East Asian population with an overall allele frequency of 1.1% (157/14796 alleles with 42 hemizygotes) in the Genome Aggregation Database. The arginine at codon 459 is moderately conserved and is located in the dehydrogenase domain. Additionally, another missense variant at the same amino acid (p.Arg459Pro) has been observed in individuals with G6PD deficiency and is considered pathogenic (Calabro 1993). Based on available information, the p.Arg459Leu variant is considered to be pathogenic. References: Calabro V et al. Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency revealed by single-strand conformation and sequence analysis. Am J Hum Genet. 1993 Mar;52(3):527-36. Fu C et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. Sci Rep. 2018 Jan 16;8(1):833. Stevens D et al. G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg----Leu mutation. Nucleic Acids Res. 1990: 18(23):7190. Tang T et al. Diverse point mutations result in glucose-6-phosphate dehydrogenase (G6PD) polymorphism in Taiwan. Blood. 1992: 79(8):2135-40. -
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicOct 20, 2022PP4, PP5, PM5, PS3, PS4_moderate -
Pathogenic, criteria provided, single submitterclinical testingGeneDxJun 04, 2023In vitro functional studies indicate that R459L has a reduced catalytic efficiency of approximately 50% compared to wild type enzyme (Boonyuen et al., 2017); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 9891846, 34659341, 34746046, 2263506, 11499668, 14505231, 1953767, 29783823, 29339739, 11793482, 31374327, 34570182, 12215013, 34953813, 29251006, 35193651, 28376293, 35313968, 8571933, 28583873) -
Pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Nov 09, 2015- -
G6PD deficiency Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaApr 05, 2019The G6PD c.1376G>T (p.Arg459Leu) missense variant, also described as G6PD Canton, is one of the most common glucose-6-phosphate dehydrogenase (G6PD) deficiency variants in certain Asian populations. Across a selection of the available literature, the p.Arg459Leu variant was observed in 116 G6PD deficiency cases, mostly in individuals of Chinese ancestry (Stevens et al. 1990; Tang et al. 1992; Cai et al. 2000; Deng et al. 2007; Phompradit et al. 2011; Yang et al. 2014). Control data are unavailable for the p.Arg459Leu variant, which is reported at a frequency of 0.01061 in the East Asian population of the Genome Aggregation Database including 42 hemizygotes in this population and 43 hemizygotes in the total population. Based on the evidence, the p.Arg459Leu variant is classified as pathogenic for glucose-6-phosphate dehydrogenase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Pathogenic, no assertion criteria providedcurationReproductive Health Research and Development, BGI GenomicsJan 06, 2020NM_001042351.1:c.1376G>T in the G6PD gene has an allele frequency of 0.012 in East Asian subpopulation in the gnomAD database. The c.1376G>T (p.Arg459Leu) variant was observed in numerous G6PD deficiency cases, mostly in individuals of Chinese ancestry (PMID: 25440321; 22171972; 21874587). Experimental studies have shown that this missense change causes a significant reduction in enzyme activity and affinity for glucose-6-phosphate (PMID: 16607506). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. Pathogenic computational verdict because pathogenic predictions from DANN, DEOGEN2, FATHMM-MKL, MVP, MutationTaster and REVEL. ACMG/AMP Criteria applied: PS3; PS4; PP4; PP3. -
Malaria, susceptibility to;C2720289:Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsMar 18, 2022- -
Malaria, susceptibility to Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 28, 2024- -
G6PD-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesApr 27, 2024The G6PD c.1376G>T variant is predicted to result in the amino acid substitution p.Arg459Leu. This variant, referred to as G6PD Canton, has previously been reported to causative for Glucose-6-Phosphate Dehydrogenase deficiency (Wang X et al 2021. PubMed ID: 34659341; Nuchprayoon I et al 2002. PubMed ID: 11793482; Stevens et al 1990. PubMed ID: 2263506; Yusoff NM et al 2002. PubMed ID: 12215013). This variant is interpreted as pathogenic. -
G6PD AGRIGENTO Other:1
other, no assertion criteria providedliterature onlyOMIMMay 24, 2017- -
G6PD TAIWAN-HAKKA Other:1
other, no assertion criteria providedliterature onlyOMIMMay 24, 2017- -
G6PD GIFU Other:1
other, no assertion criteria providedliterature onlyOMIMMay 24, 2017- -
G6PD CANTON Other:1
other, no assertion criteria providedliterature onlyOMIMMay 24, 2017- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.37
BayesDel_addAF
Pathogenic
0.25
D
BayesDel_noAF
Pathogenic
0.59
CADD
Benign
23
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.91
D;D;D;.
FATHMM_MKL
Uncertain
0.91
D
LIST_S2
Pathogenic
0.99
.;.;D;D
MetaRNN
Benign
0.014
T;T;T;T
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Benign
1.7
L;L;L;.
MutationTaster
Benign
1.0
D;D;D;D
PrimateAI
Uncertain
0.76
T
PROVEAN
Uncertain
-2.8
.;.;D;D
REVEL
Pathogenic
0.70
Sift
Benign
0.12
.;.;T;T
Sift4G
Benign
0.14
T;.;T;T
Polyphen
0.73
P;P;P;.
Vest4
0.56
MVP
1.0
MPC
1.9
ClinPred
0.20
T
GERP RS
5.6
Varity_R
0.72
gMVP
0.96

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs72554665; hg19: chrX-153760484; API